Celsion Announces Treatment Of First Patient In China In Global Phase III ThermoDox(R) Trial For Primary Liver Cancer

Celsion Corporation, a leading oncology drug development company, announced today that the first patient in China has been enrolled and treated as part of Celsion’s global Phase III ThermoDox HEAT trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer. Following recent regulatory approvals in China, Malaysia and the Philippines, the study is now recruiting patients in ten of eleven planned countries, with the majority of clinical sites located in the Asia Pacific region where HCC is most prevalent…

Go to Source

People who read this also read

• Antares Pharma Announces Completion Of Patient Enrollment In Phase 3 Pivotal Trial Of Anturol™ For The Treatment Of Overactive Bladder
  Antares Pharma, Inc. (NYSE Amex: AIS) announced that it has completed enrollment in the double-blind portion of the Company's Phase 3 clinical trial of Anturol™, its transdermal oxybutynin ATD™ gel for the treatment of overactive bladder (OAB). Top line data from this pivotal trial, which is being c...
• Celsion Plans To Launch Phase II Program To Study ThermoDox(R) In Combination With RFA For Colorectal Liver Metastases
  Celsion Corporation (Nasdaq: CLSN) announced that it will initiate a Randomized Phase II Study of Lyso-Thermosensitive Liposomal Doxorubicin (ThermoDox®) and Radiofrequency Ablation (RFA) for Colorectal Liver Metastases (CRLM). Dr. Steven K. Libutti, Professor and Vice Chairman, Department of Surger...
• ThromboGenics Completes Patient Enrolment Of Second Phase III Trial Of Microplasmin For The Non-Surgical Treatment Of Eye Disease
  ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that it has completed the enrolment of the second Phase III trial evaluating microplasmin for the non...
• Biocancell Receives U.S. FDA Approval To Continue Phase IIb Superficial Bladder Cancer Clinical Trial And Interim Results
  Tikcro Technologies Ltd. (OTC BB: TIKRF) announced that BioCancell Therapeutics, Inc. ("Biocancell"), concluded the first 18 patient group treated pursuant to a Phase IIb clinical trial of the drug candidate BC-819 for use in superficial bladder cancer. These patients had not responded to convention...
• New Data From Phase III Lung Cancer Trial Show VeriStrat(R) Identifies Patients Likely To Respond To Erlotinib
  Results from the VeriStrat biomarker analysis of a multicenter Phase III trial were presented at the 2nd European Lung Cancer Conference currently being held in Geneva, Switzerland. Results showed that the VeriStrat test identified patients who were likely to have a survival benefit from treatment ...